Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated *BRAF* V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero, MD, PhD; Axel Grothey, MD; Eric Van Cutsem, MD, PhD; Rona Yaeger, MD; Harpreet Wasan, MD; Takayuki Yoshino, MD, PhD; Jayesh Desai, MBBS; Fortunato Ciardiello, MD, PhD; Fotios Loupakis, MD, PhD; Yong Sang Hong, MD, PhD; Neeltje Steeghs, MD, PhD; Tormod Kyrre Guren, MD, PhD; Hendrik-Tobias Arkenau, MD, PhD; Pilar Garcia-Alfonso, MD; Elena Elez, MD, PhD; Ashwin Gollerkeri, MD; Kati Maharry, PhD; Janna Christy-Bittel, MSN; and Scott Kopetz, MD, PhD

**abstract**

**PURPOSE** BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators’ choice of irinotecan or FOLFIRI plus cetuximab in patients with *BRAF* V600E–mutant metastatic colorectal cancer (mCRC), after progression on 1–2 prior regimens. In the previously reported primary analysis, encorafenib, binimetinib plus cetuximab (ENCO/BINI/CETUX; triplet) and encorafenib plus cetuximab (ENCO/CETUX; doublet) regimens improved overall survival (OS) and objective response rate (ORR; by blinded central review) versus standard of care. The purpose of this analysis was to report updated efficacy and safety data.

**METHODS** In this open-label, phase III trial, 665 patients with *BRAF* V600E–mutant mCRC were randomly assigned 1:1:1 to receive triplet, doublet, or control. Primary end points were OS and independently reviewed ORR comparing triplet to control. OS for doublet versus control was a key secondary end point. Updated analyses include 6 months of additional follow-up and ORR for all randomized patients.

**RESULTS** Patients received triplet (n = 224), doublet (n = 220), or control (n = 221). Median OS was 9.3 months (95% CI, 8.2 to 10.8) for triplet and 5.9 months (95% CI, 5.1 to 7.1) for control (hazard ratio [HR], 0.60 [95% CI, 0.47 to 0.75]). Median OS for doublet was 9.3 months (95% CI, 8.0 to 11.3) (HR versus control, 0.61 [95% CI, 0.48 to 0.77]). Confirmed ORR was 26.8% (95% CI, 21.1% to 33.1%) for triplet, 19.5% (95% CI, 14.5% to 25.4%) for doublet, and 1.8% (95% CI, 0.5% to 4.6%) for control. Adverse events were consistent with the prior primary analysis, with grade ≥ 3 adverse events in 65.8%, 57.4%, and 64.2% for triplet, doublet, and control, respectively.

**CONCLUSION** In the BEACON CRC study, encorafenib plus cetuximab improved OS, ORR, and progression-free survival in previously treated patients in the metastatic setting compared with standard chemotherapy. Based on the primary and updated analyses, encorafenib plus cetuximab is a new standard care regimen for previously treated patients with *BRAF* V600E mCRC.

J Clin Oncol 39:273-284. © 2021 by American Society of Clinical Oncology

**INTRODUCTION**

Mutations in *BRAF* are recurrently detected in human cancer, including melanoma, colorectal, thyroid, non–small-cell lung, and hairy cell leukemia.1 *BRAF* encodes a serine/threonine protein kinase that is part of the RAS/RAF/MEK/ERK pathway. The majority of mutations in *BRAF* result in V600E substitution, and these patients generally have a poor prognosis.2,3 Approximately 10% of patients with metastatic colorectal cancer (mCRC) have a *BRAF* mutation, with recent estimates ranging from as low as 5% to as high as 21%.1,4-10 *BRAF* V600E mutation results in downstream phosphorylation of MEK and ERK, leading to constitutive activation of the mitogen-activated protein kinase (MAPK) signaling pathway, which drives tumor cell proliferation and survival.1

New therapeutic strategies for the *BRAF* V600E–mutant mCRC population are warranted as standard cytotoxic combinations result in a modest benefit in the first-line setting and limited benefits in the second-line and...
**CONTEXT**

**Key Objective**
The BEACON trial evaluated the safety and efficacy of encorafenib plus cetuximab with or without binimetinib in previously treated patients with *BRAF* V600E–mutant metastatic colorectal cancer (mCRC). This paper reports updated data from BEACON sponsored by Array BioPharma in collaboration with Merck, ONO Pharmaceutical, and Pierre Fabre. Array BioPharma was acquired by Pfizer in July 2019.

**Knowledge Generated**
Encorafenib plus cetuximab (with or without binimetinib) demonstrated significantly improved survival and tumor response, compared with standard chemotherapy plus cetuximab, with a similar initially reported safety profile. The binimetinib addition did not increase overall efficacy and was associated with additional MEK inhibitor-related adverse events.

**Relevance**
Encorafenib plus cetuximab may be a new regimen for patients with *BRAF* V600E–mutant mCRC whose disease progressed after one or two prior regimens. Further work may be warranted to explore if this regimen may serve as a backbone for the addition of other targeted agents and/or chemotherapy for *BRAF*–mutant mCRC.

Encorafenib is a BRAF inhibitor with prolonged pharmacodynamic activity compared with other available BRAF inhibitors. The doublet combination of the BRAF inhibitor encorafenib and the anti-EGFR monoclonal antibody cetuximab showed promise in early clinical trials. The BEACON CRC study evaluated whether the combination of encorafenib plus cetuximab with or without the MEK inhibitor binimetinib could improve overall survival (OS) compared with standard therapy in patients with *BRAF* V600E–mutated mCRC whose disease has progressed after one or two prior lines of therapy. The study was a randomized, three-arm, phase III study that evaluated encorafenib plus cetuximab with or without binimetinib versus investigators’ choice of irinotecan plus cetuximab or FOLFIRI (folinic acid, fluorouracil, and irinotecan) plus cetuximab in 665 patients with *BRAF* V600E–mutant mCRC whose disease had progressed after one or two prior regimens. In a prespecified analysis, encorafenib plus cetuximab with or without binimetinib significantly improved OS and objective response rate (ORR) in patients with *BRAF*V600E mCRC compared with current standard of care. This study marked the first evidence of survival benefit for a chemotherapy-free targeted treatment regimen in prospectively biomarker-defined patients with mCRC, defining a new standard of care for patients with previously treated *BRAF* V600E mCRC. Complete analyses on OS and ORR as well as analyses of some prognostic subgroups may require long-term follow-up. Herein, we report updated post hoc efficacy and safety results as well as exploratory subgroup analyses of the BEACON CRC trial.

**METHODS**

**Study Design and Participants**
The design and primary analyses have been previously published (ClinicalTrials.gov identifier: NCT02928224). The BEACON CRC study is a global, multicenter, randomized, open-label, phase III trial comparing encorafenib (300 mg once a day) plus binimetinib (45 mg twice a day) plus cetuximab (400 mg/m² initial dose and then 250 mg/m² once a week) (ENCO/BIN/CETUX or triplet combination), encorafenib plus cetuximab (ENCO/CETUX or doublet combination), with the control arm of investigators’ choice of either cetuximab combined with irinotecan alone (180 mg/m² on days 1 and 15) or cetuximab combined with FOLFIRI. Eligible patients were randomly assigned in a 1:1:1 ratio and stratified by ECOG performance status (0/1), prior use of irinotecan (yes/no), and cetuximab formulation (United States–licensed vs European Union–approved).

Patients with histologically or cytologically confirmed mCRC with centrally confirmed *BRAF* V600E mutation and progression after one or two prior treatment regimens for metastatic disease were eligible for this trial. Prior BRAF, MEK, or EGFR inhibitors were not permitted. The full list of
inclusion and exclusion criteria is in the study Protocol (online only).

**Study End Points**

The primary end points of the trial were OS for the triplet combination compared with the control and ORR (by blinded independent central review) for the triplet combination compared with the control. OS for the doublet arm compared with the control arm was defined as a key secondary end point. Other secondary end points included progression-free survival (PFS), duration of response (DOR; defined as time from first radiographic evidence of response [complete or partial response] to the earliest documented disease progression or death due to any cause), safety, and a comparison of ORR and OS between the doublet and triplet arms. Tumor assessments were performed according to RECIST v1.1 prior to random assignment and every 6 weeks from the date of random assignment for the first 24 weeks of treatment and then every 12 weeks thereafter until disease progression, withdrawal of consent, initiation of subsequent anticancer therapy, patient lost to follow-up, or death, regardless of whether study treatment had been discontinued. Assessments deemed as responses were confirmed with subsequent imaging obtained at least 4 weeks after the first response. The central review of imaging data was performed retrospectively by readers blinded to treatment assignment. The incidence and severity of adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03.

The BEACON CRC study was conducted in accordance with the requirements of each country’s regulatory authorities as well as the provisions of the Declaration of Helsinki and Good Clinical Practice guidelines, as defined by the International Council for Harmonisation. All patients who participated in the trial provided written informed consent. This trial was approved by the institutional review board or independent ethics committee at each center.

**Statistical Analysis**

An updated analysis was conducted after an additional 6 months of follow-up relative to the primary analysis (February 11, 2019) with a data cutoff of August 15, 2019. Time-to-event end points and ORR were analyzed based on all randomly assigned patients (ie, intention to treat population). Safety was evaluated by assessments of adverse events and laboratory abnormalities in patients who received at least one dose of trial drug and had at least one post-treatment safety assessment. Subgroup analyses were performed for OS and ORR for all randomly assigned patients who had available data at baseline for a given subgroup. For OS, Cox proportional hazards models were used to estimate the hazard ratio (HR) and corresponding 95% CI for each subgroup, comparing the treatment arms in a pairwise manner. The Kaplan–Meier method was used to calculate the median OS, and corresponding 95% CIs were determined for each subgroup. Forest plots were generated for visual representation of these results. For ORR, response rates (the number of patients achieving an overall best response of complete response or partial response divided by the total number of patients) by Blinded Independent Central Review per RECIST v1.1 were calculated for each subgroup by treatment arm.

Results of this post hoc analysis are descriptive with no formal hypothesis tests conducted. The study was not

**TABLE 1. Patient Disposition**

| Patient Disposition Category                                      | ENCO/BIN/ CETUX (n = 224) | ENCO/ CETUX (n = 220) | Control (n = 221) |
|------------------------------------------------------------------|----------------------------|-----------------------|-------------------|
| Randomly assigned, not treated                                   | 2 (0.9)                   | 4 (1.8)               | 28 (12.7)         |
| Treatment ongoing                                                | 30 (13.4)                 | 30 (13.6)             | 7 (3.2)           |
| Treatment discontinued                                           | 192 (85.7)                | 186 (84.5)            | 186 (84.2)        |
| Progressive disease                                             | 140 (62.5)                | 145 (65.9)            | 123 (55.7)        |
| Changes in the patient’s condition or development of an intercurrent illness | 14 (6.3)                  | 11 (5.0)              | 16 (7.2)          |
| Unacceptable AEs or failure to tolerate study drug              | 13 (5.8)                  | 11 (5.0)              | 10 (4.5)          |
| Death                                                            | 8 (3.6)                   | 6 (2.7)               | 11 (5.0)          |
| Withdrawal of consent                                           | 4 (1.8)                   | 3 (1.4)               | 11 (5.0)          |
| Dose interruption of > 28 consecutive days (encorafenib or binimetinib) or 2 missed consecutive irinotecan, fluorouracil, or folinic acid, or > 4 missed consecutive cetuximab doses | 4 (1.8)                   | 2 (0.9)               | 6 (2.7)          |
| Patient decision to discontinue study treatment                 | 3 (1.3)                   | 3 (1.4)               | 5 (2.3)           |
| Physician decision                                              | 2 (0.9)                   | 4 (1.8)               | 2 (0.9)           |
| Other                                                            | 3 (1.3)                   | 1 (0.5)               | 1 (0.5)           |
| Receipt of subsequent anticancer therapy                        | 1 (0.4)                   | 0 (0.0)               | 1 (0.5)           |

Abbreviations: AE, adverse event; ENCO/BIN/CETUX, encorafenib, binimetinib plus cetuximab; ENCO/CETUX, encorafenib plus cetuximab.
powered to formally compare the results of the triplet combination with the doublet combination. Additional details regarding the trial design, sample size calculations, and analysis methods have been previously published.24

RESULTS

Patients

A total of 665 patients were enrolled from May 2017 to January 2019 and were randomly assigned to receive the triplet combination \((n = 224)\), doublet combination \((n = 220)\), or one of the control regimens \((n = 221)\) (Table 1). The primary analysis was based on a data cutoff of February 11, 2019 (Data Supplement, online only) and has been previously published.24 At the time of the data cutoff date for the current report, 13.4% of patients in the triplet arm, 13.6% in the doublet arm, and 3.2% in the control arm were receiving study treatment. Overall, baseline demographic and clinical characteristics were generally similar in the three randomized phase III treatment arms, although there were trends to higher multiorgan involvement, elevated carcinoembryonic antigen \((> 5 \mu g/L)\), and C-reactive protein \((CRP) > 10 \text{ mg/L}) in the triplet arm (Table 2).

### TABLE 2. Baseline Characteristics of Randomly Assigned Patients

| Characteristic                                      | ENCO/BINI/CETUX \((n = 224)\) | ENCO/CETUX \((n = 220)\) | Control \((n = 221)\) |
|----------------------------------------------------|-------------------------------|--------------------------|----------------------|
| Sex, \(n (%))                                       |                               |                          |                      |
| Male                                               | 105 (47)                      | 114 (52)                 | 94 (43)              |
| Female                                             | 119 (53)                      | 106 (48)                 | 127 (57)             |
| Age, years                                          |                               |                          |                      |
| Median                                             | 62                            | 61                       | 60                   |
| Min, max                                           | 26, 85                        | 30, 91                   | 27, 91               |
| ECOG PS, \(n (%))                                   |                               |                          |                      |
| 0                                                  | 116 (52)                      | 112 (51)                 | 108 (49)             |
| 1                                                  | 108 (48)                      | 104 (47)                 | 113 (51)             |
| 2                                                  | 0 (0)                         | 4 (2)                    | 0 (0)                |
| Location of primary tumor, \(n (%))                 |                               |                          |                      |
| Left colon (includes rectum)                        | 79 (35)                       | 83 (38)                  | 68 (31)              |
| Right colon                                         | 126 (56)                      | 110 (50)                 | 119 (54)             |
| Other\(^a\)                                         | 19 (8)                        | 27 (12)                  | 34 (15)              |
| \(\geq 3\) organs involved, \(n (%))               | 110 (49)                      | 103 (47)                 | 98 (44)              |
| Presence of liver metastases, \(n (%))              | 145 (65)                      | 134 (61)                 | 128 (58)             |
| Primary tumor removed, \(n (%))                     |                               |                          |                      |
| Completely resected                                  | 133 (59)                      | 123 (56)                 | 122 (55)             |
| Partially resected or unresected                     | 91 (41)                       | 97 (44)                  | 99 (45)              |
| Prior lines of therapy, \(n (%))                    |                               |                          |                      |
| 1                                                  | 146 (65)                      | 146 (66)                 | 145 (66)             |
| 2\(^b\)                                            | 78 (35)                       | 74 (34)                  | 76 (34)              |
| Prior oxaliplatin, \(n (%))                         | 199 (89)                      | 210 (95)                 | 201 (91)             |
| MSI-H\(^c\), \(n (%))                              | 22 (10)                       | 19 (9)                   | 12 (5)               |
| CEA baseline value \(> 5 \mu g/L, n (%))             | 179 (80)                      | 153 (70)                 | 178 (81)             |
| CRP baseline value \(> 10 \text{ mg/L}, n (%))       | 95 (42)                       | 79 (36)                  | 90 (41)              |

NOTE. Baseline characteristics are summarized for all 665 randomly assigned patients. Total percentages may not add to 100% due to rounding. Abbreviations: CEA, carcinoembryonic antigen; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ENCO/BINI/CETUX, encorafenib, binimetinib plus cetuximab; ENCO/CETUX, encorafenib plus cetuximab; MSI-H, microsatellite instability high (high).\(^a\)Other refers to patients with primary tumor in both left and right sides of colon and those with unknown location of primary tumor.\(^b\)One patient on the triplet arm and one patient on the control arm received more than two prior lines of therapy.\(^c\)Based on assessment by polymerase chain reaction (PCR), 17% of patients were not evaluable or had missing MSI measurement by PCR.

Efficacy

The median duration of follow-up for survival was 12.8 months across the arms as of the data cutoff date for this analysis (August 15, 2019). The Kaplan–Meier curves for OS are presented in Figure 1. The triplet combination resulted in a median OS of 9.3 months (95% CI, 8.2 to 10.8) compared with 5.9 months (95% CI, 5.1 to 7.1) for the control group, with a 40% reduction in the hazard of
decrease in death on study compared with the control arm (HR of 0.60; 95% CI, 0.47 to 0.75). Similarly, the doublet combination resulted in a median OS of 9.3 months (95% CI, 8.0 to 11.3), with a 39% reduction in the risk of death compared with control with a HR of 0.61 (95% CI, 0.48 to 0.77). The OS results were similar between triplet and doublet with a HR of 0.95 (95% CI, 0.74 to 1.21).

The results for subgroups were generally consistent with the overall analysis (Fig 2). Both triplet and doublet showed improved OS compared with control in all subgroups. The triplet group was compared with doublet in a separate subgroup analysis. The results for patients with high baseline levels of CRP (HR, 0.76 [95% CI, 0.54 to 1.06]), ECOG performance status of 1 (HR, 0.81 [95% CI, 0.59 to 1.11]), incompletely resected primary tumor (HR, 0.80 [95% CI, 0.56 to 1.14]), and ≥3 organ involvement (HR, 0.69 [95% CI, 0.49 to 0.96]) appeared to favor triple therapy relative to doublet therapy.

Confirmed ORR results by blinded independent review based on all randomly assigned patients were 26.8% (95% CI, 21.1 to 33.1) for triplet, 19.5% (95% CI, 14.5 to 25.4) for doublet, and 1.8% (95% CI, 0.5 to 4.6) for control (Table 3). Responses assessed by local investigators were similar to central review. The response rates for patients with only 1 prior line of therapy were 28% (95% CI, 21.1 to 36) for the triplet therapy, 20% (95% CI, 14 to 27) for the doublet combination, and 2% (95% CI, < 1 to 6) for the control. For patients with more than one prior line of therapy, response rates were 24% (95% CI, 15 to 35) for the triplet therapy, 19% (95% CI, 11 to 30) for the doublet combination, and 1% (95% CI, < 1 to 7) for the control. Patients in the triplet arm had a median DOR of 4.4 months (95% CI, 3.7 to 7.3), patients in the doublet arm had a median DOR of 5.5 months (95% CI, 4.1 to 8.3), and the four patients with a response in the control arm had a median DOR of 5.5 months (95% CI, 2.6 to NR). Nineteen of the 60 confirmed responders (31.7%) in the triplet arm had a response that was at least 6 months in duration, and another 4 (6.7%) had responses that were < 6 months in duration, but still ongoing at the data cutoff. In the doublet arm, 16 of the 43 confirmed responders (37%) had a response that lasted for at least 6 months in duration, with another 4 (9%) that were ongoing, but < 6 months in duration. In the control arm, one of the four confirmed responders had a response that was at least 6 months in duration and no ongoing responses. Waterfall plots showing the best percentage change from baseline in the sum of the diameters of the target lesions in each treatment arm are provided in the Data Supplement.

Both the triplet and doublet combinations prolonged PFS by blinded independent central review relative to the control arm; median PFS was 4.5 months (95% CI, 4.2 to 5.4), 4.3 months (95% CI, 4.1 to 5.4), and 1.5 months (95% CI, 1.5 to 1.9) for triplet, doublet, and control, respectively (Fig 3), with HRs of 0.42 (95% CI, 0.33 to 0.53) for triplet compared with the control and 0.44 (95% CI, 0.35 to 0.55) for doublet compared with the control.

After study drug discontinuation, subsequent systemic treatments were received by 104 (46%) of 224 patients in the triplet arm, 99 (45%) of 220 in the doublet arm, and 104 (47%) of 221 in the control arm. In the triplet arm, subsequent systemic therapies of interest were fluorouracil (25.0%), irinotecan (24.6%), folinic acid (16.5%), bevacizumab (9.8%), oxaliplatin (6.7%), cetuximab (5.8%), regorafenib (5.4%), and TAS-102 (4.0%). In the

FIG 1. Overall survival results. (A) ENCO/BINI/CETUX versus control. (B) ENCO/CETUX versus control. ENCO/BINI/CETUX, encorafenib, binimetinib plus cetuximab; ENCO/CETUX, encorafenib plus cetuximab; HR, hazard ratio; OS, overall survival.
doublet arm, subsequent systemic therapies of interest included irinotecan (26.8%), fluorouracil (25.9%), bevacizumab (12.7%), oxaliplatin (8.2%), afiblercept (5.5%), regorafenib (5.5%), capecitabine (4.1%), cetuximab (4.1%), and TAS-102 (2.3%). In the control arm, subsequent systemic therapies of interest were fluorouracil (19.9%), irinotecan (16.3%), cetuximab (14.5%), oxaliplatin (13.1%), bevacizumab (10.9%), vemurafenib (9.5%), TAS-102 (7.2%), and regorafenib (5.0%). BRAF/MEK/EGFR inhibitor combinations were administered in four patients (2%), one patient (0.5%), and 18 patients (8%), whereas BRAF/EGFR inhibitor combinations were administered in 3 patients (1%), 1 patient (0.5%), and 4 patients (2%) in the triplet, doublet, and control arms, respectively. Subsequent immunotherapy was received by < 10% of patients in each treatment arm.

Safety

Safety results for the triplet and doublet arms relative to the control arm are consistent with the primary analysis and show no new safety signals. The median duration of exposure to study drugs was 21 weeks in the triplet arm, 19 weeks in the doublet arm, and 7 weeks in the control arm. The most frequently occurring adverse events regardless of assessed causality are summarized in Table 4. The most frequently reported adverse events (all grades) in the triplet arm were diarrhea (66.2%), dermatitis acniform (50.0%), anemia (48.2%), nausea (45.9%), vomiting (44.1%), abdominal pain (34.2%), fatigue (33.3%), decreased appetite (29.7%), constipation (28.4%), and asthenia (27.9%). In the doublet arm, the most frequently reported adverse events were diarrhea (38.4%), nausea (38.0%), fatigue (33.3%), decreased appetite (31.0%), and dermatitis acniform (30.1%). In the

FIG 2. Subgroup analysis of overall survival. (A) ENCO/BINI/CETUX versus control. (B) ENCO/CETUX versus control. (C) ENCO/BINI/CETUX versus ENCO/CETUX. CEA, carcinoembryonic antigen; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ENCO/BINI/CETUX, encorafenib, binimetinib plus cetuximab; ENCO/CETUX, encorafenib plus cetuximab; MSI, microsatellite instability.
control arm, the most frequently reported adverse events were diarrhea (48.7%), nausea (43.5%), dermatitis acneiform (39.9%), vomiting (31.6%), decreased appetite (29.0%), fatigue (28.0%), abdominal pain (28.0%), and asthenia (27.5%). Dermatitis acneiform, diarrhea, nausea, constipation, and vomiting were reported at a higher incidence (> 10.0% difference in incidence) in the triplet arm than the doublet arm, whereas headache, arthralgia, and melanocytic nevus were reported at a higher incidence in the doublet arm than the triplet arm. Lab abnormalities of interest in > 10% of patients are reported in Table 4. Grade 3 or greater adverse events were observed in 66%, 57%, and 64% of patients treated with the triplet, doublet, and control regimens, respectively. Discontinuation of all therapy primarily due to an adverse event was seen in 9% of patients in the triplet arm, 9% in the doublet arm, and 11% in the control arm. Deaths resulting from AEs occurred in 5%, 4%, and 4% of patients treated with the triplet, doublet, and control regimens, respectively. Investigators deemed three of the deaths to be at least possibly related to treatment: one death was from colonic perforation (triplet), one was from anaphylaxis (control), and one was from respiratory failure (control).

DISCUSSION

In these updated analyses of the phase III BEACON CRC study, the doublet encorafenib plus cetuximab regimen had similar overall efficacy to the triplet regimen, indicating that this regimen could be effectively used in patients with BRAF V600E–mutant mCRC whose disease had progressed after one or two prior regimens. Both the triplet and doublet regimens had an acceptable safety profile and significant clinically meaningful benefits relative to the control arm. Both regimens improved OS, ORR, and PFS compared with investigators’ choice of cetuximab plus irinotecan-based chemotherapy in patients with BRAF V600E–mutant mCRC whose disease had progressed after one or two prior regimens. The control arm performed as expected based on prior experience in a similar population.
and published prospective and retrospective analyses.\textsuperscript{1,11,26-28} An assessment of subsequent treatment following BEACON suggests that additional lines of therapy did not differ between the triplet and doublet treatment arms and so were unlikely to have a major influence on the OS results.

Safety results for the triplet and doublet arms relative to the control arm are consistent with the primary analysis and the known safety profile of MEK, BRAF, and EGFR inhibitors, and no new safety signals were observed. Both treatment arms were similar in the rate of adverse events. Despite a longer median duration of exposure to study treatment in the triplet and doublet arms relative to the control arm (21, 19, and 7 weeks in the triplet, doublet, and control arms, respectively), the frequency of grade 3 or higher toxicity was slightly higher in the control and triplet arms than in the doublet arm. Binimetinib as part of the triple combination does add some additional toxicity associated with MEK inhibition but also had a mitigating effect in some specific toxicities (eg, headache, arthralgia, myalgia, and melanocytic nevi). Class-related toxicities of MEK inhibitors including serous retinopathy and left ventricular dysfunction occurred at rates similar to that previously described\textsuperscript{20,29} and were managed with treatment interruptions with or without subsequent dose reduction. The triplet and doublet regimens had similar rates of treatment discontinuation.

The study was not powered to compare the 2 experimental arms directly; however, the updated descriptive analyses comparing the triplet and doublet arms showed similar efficacy in the overall population across end points including OS and PFS. These results suggest that the doublet regimen is sufficient to maximize the OS benefit and is the optimal regimen for this patient population. The United States Food and Drug Administration approved the doublet for the treatment of \textit{BRAF} V600E–mutant mCRC after prior therapy in April 2020. The doublet regimen will be a useful therapeutic backbone to explore the utility of novel targeted
agents and/or chemotherapy combinations for patients with \textit{BRAF} V600E–mutant mCRC.

Subgroup analyses suggested that patients with several poor prognostic indicators may benefit from the addition of binimetinib across primary and secondary end points, including the contribution to higher response rates (Fig 2C). For example, elevations in the tumor marker CRP are associated with poor outcomes in patients with mCRC,\textsuperscript{30,31} and the subgroup of patients with elevated CRP appeared to have better OS outcomes with the triplet regimen versus the doublet regimen (Fig 2C). Interestingly, specific toxicities were lower in the triplet regimen. Further prospective research is warranted to validate these observations and better define the relative benefits of the triplet and doublet regimens.

In conclusion, these updated analyses of the BEACON CRC study confirmed that encorafenib plus cetuximab with or without binimetinib improved OS, ORR, and PFS in previously treated patients with \textit{BRAF} V600E–mutant mCRC compared with the study control.

### TABLE 3. Tumor Response in Patients With \textit{BRAF} V600E–Mutant Metastatic Colorectal Cancer by Treatment Arm as Assessed by Blinded Independent Central Review

| Central assessment\textsuperscript{a} | ENCO/BINI/CETUX (n = 224) | ENCO/CETUX (n = 220) | Control (n = 221) |
|----------------------------------------|---------------------------|----------------------|------------------|
| ORR, n (%)                             | 60 (27)                   | 43 (20)              | 4 (2)            |
| 95\% CI                                | 21 to 33                  | 15 to 25             | < 1 to 5         |
| \textit{P} value v control             | < 0.0001                  | < 0.0001             |                  |

| Best overall response, n (%)\textsuperscript{b} | ENCO/BINI/CETUX | ENCO/CETUX | Control |
|-----------------------------------------------|----------------|------------|---------|
| CR                                           | 8 (4)          | 7 (3)      | 0       |
| PR                                           | 52 (23)        | 36 (16)    | 4 (2)   |
| Stable disease\textsuperscript{c}            | 108 (48)       | 124 (56)   | 65 (29) |
| Progressive disease                           | 24 (11)        | 21 (10)    | 82 (37) |
| Nonevaluable by RECIST\textsuperscript{d}    | 32 (14)        | 32 (15)    | 70 (32) |

Abbreviations: CR, complete response; ENCO/BINI/CETUX, encorafenib, binimetinib plus cetuximab; ENCO/CETUX, encorafenib plus cetuximab; ORR, objective response rate; PR, partial response.

\textsuperscript{a}Confirmed responses per RECIST 1.1.

\textsuperscript{b}ORR equals the percentage of patients with a CR or a PR.

\textsuperscript{c}Stable disease includes measurable disease patients who were either stable disease or nonmeasurable disease patients who were non-CR/nonprogressive disease per RECIST 1.1.

\textsuperscript{d}This category includes patients who had a confirmed PR as determined by local assessment (these patients underwent scanning at outside institutions at baseline, and the scans were not available for central assessment).

---

![FIG 3](image-url). Progression-free survival by blinded independent central review. (A) ENCO/BINI/CETUX versus control. (B) ENCO/CETUX versus control. ENCO/BINI/CETUX, encorafenib, binimetinib plus cetuximab; ENCO/CETUX, encorafenib plus cetuximab; HR, hazard ratio; PFS, progression-free survival.
| Preferred Term* | ENCO/BINICETUX (n = 222) | ENCO/CETUX (n = 216) | Control (n = 193) |
|----------------|--------------------------|----------------------|------------------|
|                | Any Grade, n (%)         | Grade 3+, n (%)      | Any Grade, n (%) | Grade 3+, n (%) | Any Grade, n (%) | Grade 3+, n (%) |
| Any adverse event | 220 (99.1) | 146 (65.8) | 212 (98.1) | 124 (57.4) | 190 (98.4) | 124 (64.2) |
| Diarrhea       | 147 (66.2) | 24 (10.8) | 83 (38.4) | 6 (2.8) | 94 (48.7) | 20 (10.4) |
| Dermatitis acneiform | 111 (50.0) | 6 (2.7) | 65 (30.1) | 1 (0.5) | 77 (39.9) | 5 (2.6) |
| Nausea         | 107 (48.2) | 10 (4.5) | 82 (38.0) | 1 (0.5) | 84 (43.5) | 3 (1.6) |
| Vomiting       | 98 (44.1) | 12 (5.4) | 59 (27.3) | 3 (1.4) | 61 (31.6) | 6 (3.1) |
| Abdominal pain | 76 (34.2) | 14 (6.3) | 60 (27.8) | 7 (3.2) | 54 (28.0) | 10 (5.2) |
| Fatigue        | 74 (33.3) | 5 (2.3) | 72 (33.3) | 9 (4.2) | 54 (28.0) | 9 (4.7) |
| Decreased appetite | 66 (29.7) | 4 (1.8) | 67 (31.0) | 3 (1.4) | 56 (29.0) | 6 (3.1) |
| Constipation   | 63 (28.4) | 1 (0.5) | 39 (18.1) | 0 (0.0) | 39 (20.2) | 2 (1.0) |
| Asthenia       | 62 (27.9) | 8 (3.6) | 52 (24.1) | 8 (3.7) | 53 (27.5) | 10 (5.2) |
| Pyrexia        | 50 (22.5) | 4 (1.8) | 40 (18.5) | 3 (1.4) | 28 (14.5) | 1 (0.5) |
| Dry skin       | 48 (21.6) | 2 (0.9) | 28 (13.0) | 0 (0.0) | 16 (8.3) | 1 (0.5) |
| Rash           | 45 (20.3) | 3 (1.4) | 32 (14.8) | 0 (0.0) | 28 (14.5) | 3 (1.6) |
| Back pain      | 34 (15.3) | 3 (1.4) | 28 (13.0) | 3 (1.4) | 27 (14.0) | 2 (1.0) |
| Pruritus       | 34 (15.3) | 0 (0.0) | 24 (11.1) | 0 (0.0) | 10 (5.2) | 0 (0.0) |
| Stomatitis     | 32 (14.4) | 1 (0.5) | 13 (6.0) | 0 (0.0) | 45 (23.3) | 4 (2.1) |
| Palmar-plantar erythrodysesthesia syndrome | 31 (14.0) | 0 (0.0) | 11 (5.1) | 1 (0.5) | 15 (7.8) | 0 (0.0) |
| Edema peripheral | 30 (13.5) | 2 (0.9) | 23 (10.6) | 0 (0.0) | 14 (7.3) | 1 (0.5) |
| Vision blurred | 27 (12.2) | 0 (0.0) | 10 (4.6) | 0 (0.0) | 1 (0.5) | 0 (0.0) |
| Cough          | 26 (11.7) | 0 (0.0) | 20 (9.3) | 1 (0.5) | 11 (5.7) | 0 (0.0) |
| Urinary tract infection | 26 (11.7) | 3 (1.4) | 17 (7.9) | 5 (2.3) | 6 (3.1) | 2 (1.0) |
| Arthralgia     | 25 (11.3) | 0 (0.0) | 49 (22.7) | 3 (1.4) | 3 (1.6) | 0 (0.0) |
| Weight decreased | 24 (10.8) | 1 (0.5) | 24 (11.1) | 1 (0.5) | 12 (6.2) | 0 (0.0) |
| Abdominal pain upper | 23 (10.4) | 1 (0.5) | 22 (10.2) | 2 (0.9) | 15 (7.8) | 1 (0.5) |
| Dyspnea        | 22 (9.9) | 2 (0.9) | 28 (13.0) | 2 (0.9) | 20 (10.4) | 6 (3.1) |
| Myalgia        | 20 (9.0) | 0 (0.0) | 33 (15.3) | 1 (0.5) | 4 (2.1) | 0 (0.0) |
| Headache       | 19 (8.6) | 0 (0.0) | 43 (19.9) | 0 (0.0) | 5 (2.6) | 0 (0.0) |
| Pain in extremity | 17 (7.7) | 0 (0.0) | 25 (11.6) | 0 (0.0) | 2 (1.0) | 0 (0.0) |
| Insomnia       | 14 (6.3) | 0 (0.0) | 24 (11.1) | 0 (0.0) | 13 (6.7) | 0 (0.0) |
| Musculoskeletal pain | 10 (4.5) | 0 (0.0) | 29 (13.4) | 0 (0.0) | 5 (2.6) | 0 (0.0) |
| Melanocytic nevus | 1 (0.5) | 0 (0.0) | 34 (15.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

| Abnormal laboratory values | | | |
|-----------------------------|--|--|--|--|--|--|
| Alanine aminotransferase increase (IU/L) | 62 (27.9) | 5 (2.3) | 41 (19.0) | 1 (0.5) | 57 (29.5) | 8 (4.1) |
| Aspartate aminotransferase increase (IU/L) | 61 (27.5) | 6 (2.7) | 40 (18.5) | 4 (1.9) | 43 (22.3) | 5 (2.6) |
| Bilirubin increase (µmol/L) | 17 (7.7) | 7 (3.2) | 18 (8.3) | 6 (2.8) | 17 (8.8) | 6 (3.1) |
| Creatine kinase increase (IU/L) | 67 (30.2) | 9 (4.1) | 8 (3.7) | 0 | 14 (7.3) | 1 (0.5) |
| Creatinine increase (µmol/L) | 176 (79.3) | 12 (5.4) | 116 (53.7) | 7 (3.2) | 73 (37.8) | 2 (1.0) |
| Hemoglobin decrease (g/L) | 154 (69.4) | 52 (23.4) | 85 (39.4) | 12 (5.6) | 89 (46.1) | 10 (5.2) |

Abbreviations: ENCO/BINICETUX, encorafenib, binimetinib plus cetuximab; ENCO/CETUX, encorafenib plus cetuximab.
*Shown are adverse events of any grade and selected laboratory abnormalities reported in more than 10% of patients and adverse events of grade 3 or higher reported in more than 2% of patients in the triplet therapy group or the doublet therapy group. Grade is based on NCI CTCAE v4.03. Any single patient may have experienced adverse events under multiple terms, ie, not mutually exclusive. Reported using standard MedDRA dictionary coding.
with standard chemotherapy. Encorafenib plus cetuximab thus had similar OS efficacy with or without binimetinib, indicating that encorafenib plus cetuximab could be effectively used as the new standard of care for previously treated patients with BRAF V600E–mutant mCRC. Further work to explore whether this regimen may also serve as a suitable backbone for the addition of other targeted agents and/or chemotherapy may be warranted.

REFERENCES

1. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
2. Kayhanian H, Goode E, Sclafani F, et al: Treatment and survival outcome of BRAF-mutated metastatic colorectal cancer: A retrospective matched case-control study. Clin Colorectal Cancer 17:e69-e76, 2018
3. Tran B, Kopetz S, Tie J, et al: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623-4632, 2011
4. Sorbye H, Dragomir A, Sundström M, et al: High BRAF mutation frequency and marked survival differences in subgroups according to KRAS/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort. PLoS One 10:e0131046, 2015
5. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11:753-762, 2010
6. The ACR Project GENIE Consortium: ACR project GENIE: Powering precision medicine through an international consortium, Cancer Discov 7:818-831, 2017
7. The Cancer Genome Atlas Research Network: Comprehensive genomic characterization of squamous cell lung. Nature 489:519-525, 2012
8. Yaeger R, Chhatia WK, Lipsyc MD, et al: Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 33:125-136.e3, 2018
9. Barras D, Missiaglia E, Wirapati P, et al: BRAF V600E mutant colorectal cancer subtypes based on gene expression. Clin Cancer Res 23:104-115, 2017
10. Clarke CN, Kopetz ES: BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: Clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol 6:660-667, 2015

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.20.02088.

AUTHOR CONTRIBUTIONS
Conception and design: Josep Tabernero, Axel Groothey, Eric Van Cutsem, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Ashwin Gollerkeri, Kati Maharry, Janna Christy-Bittel, Scott Kopetz
Administrative support: Harpreet Wasan
Collection and assembly of data: Josep Tabernero, Eric Van Cutsem, Rona Yaeger, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotos Loupakis, Yong Sang Hong, Neeltje Steeghs, Tormod Guren, Pilar Garcia-Alfonso, Elena Elez, Ashwin Gollerkeri, Kati Maharry, Janna Christy-Bittel, Scott Kopetz
Data analysis and interpretation: Josep Tabernero, Axel Groothey, Eric Van Cutsem, Rona Yaeger, Harpreet Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Fotos Loupakis, Neeltje Steeghs, Tormod Guren, Hendrik-Tobias Arkenau, Pilar Garcia-Alfonso, Elena Elez, Kati Maharry, Janna Christy-Bittel, Scott Kopetz
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT
We thank the patients and their families, as well as the participating study teams, for making this study possible. J.D. Cox, PhD, of Mayville Medical Communications provided medical writing and editorial assistance. Caudek provided fact checking and editorial assistance with funding from Pfizer. A list of Steering Committee members, Data Monitoring Committee members, and Principal Investigators from participating enrolling centers, as well as a plain language summary, can be found in the Supplement.
11. Morris V, Overman MJ, Jiang Z-Q, et al: Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Col Cancer Res 13:164-171, 2014
12. Benson AB, Venook AP, Al-Hawary MM, et al: NCCN guidelines insights: Colon cancer, version 2.2018. J Natl Compr Canc Netw 16:359-369, 2018
13. Kopetz S, Desai J, Chan E, et al: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol 33:4032-4038, 2015
14. Hyman DM, Puzanov I, Subbiah V, et al: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726-736, 2015
15. Seligmann JF, Fisher D, Smith CG, et al: Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: Analysis from 2530 patients in randomised clinical trials. Ann Oncol 28:562-568, 2017
16. Privaliad A, Sun C, Huang S, et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100-103, 2012
17. Corcoran RB, Ebi H, Turke AB, et al: EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227-235, 2012
18. Hong DS, Morris VK, El Osta B, et al: Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAF V600E mutation. Cancer Discov 6:1352-1365, 2016
19. Corcoran RB, Andre T, Atreya CE, et al: Combined BRAF, EGFR, and MEK inhibition in patients with BRAF V600E-mutant colorectal cancer. Cancer Discov 8:428-443, 2018
20. Van Cutsem E, Huijbers S, Grotey A, et al: Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E–mutant metastatic colorectal cancer: Safety lead-in results from the phase III BEACON colorectal cancer study. J Clin Oncol 37:1460-1469, 2019
21. Delord JP, Robert C, Nyakas M, et al: Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res 23:5339-5348, 2017
22. Tabernero J, Van Geel R, Guren TK, et al: Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). J Clin Oncol 34:3544-3544, 2016 (15_suppl)
23. van Geel RMJ, Tabernero J, Elez E, et al: A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer. Cancer Discov 7:610-619, 2017
24. Kopetz S, Grothey A, Yaeger R, et al: Encorafenib, binimetinib, and cetuximab in BRAFV600E-mutated colorectal cancer. N Engl J Med 381:1632-1643, 2019
25. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
26. Chibaudel B, Bonnetain F, Shi Q, et al: Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: Evaluation of progression-free survival, duration of disease control, and time to failure of strategy—an Aide et Recherche en Cancerologie Digestive Group Study. J Clin Oncol 29:4199-4204, 2011
27. Kopetz S, McDonough SL, Lenz H-J, et al: Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J Clin Oncol 35, 2017 (suppl; abstr 3503)
28. Rowland A, Dias MM, Wiese MO, et al: Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112:1888-1894, 2015
29. Dummer R, Ascierto PA, Gogas HJ, et al: Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1315-1327, 2018
30. Pathak S, Nunes QM, Daniels IR, et al: Is C-reactive protein useful in prognosis for colorectal cancer? A systematic review. Colorectal Dis 16:769-776, 2014
31. Thomsen M, Kersten C, Sorbye H, et al: Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget 7:75013-75022, 2016
Authors’ Disclosures of Potential Conflicts of Interest

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/hwc or ascopubs.org/journal/jco/site/ifc.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Josep Tabernero
Consulting or Advisory Role: Bayer, Boehringer Ingelheim, Eli Lilly, MSD, Merck Serono, Novartis, Sanofi, Taiho Pharmaceutical, Merck KGaA, Roche, Sumitomo Dainippon Pharma, AstraZeneca, Genentech, GSK, Halozyme, Imugene Limited, Inflection Biosciences Limited, Kura, Menarini, Molecular Partners, Pharmacyclics, ProteoDesign SL, Roche, Seattle Genetics, Servier, VCN Biosciences, Biocartis, Foundation Medicine, HaloDX SAS, Roche Diagnostics

Axel Grothey
Consulting or Advisory Role: Elsevier, Aptitude Health
Research Funding: Genentech (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Eli Lilly (Inst), Boston Biomedical (Inst), Amgen (Inst), Array BioPharma (Inst), Guardant Health (Inst), Daiichi Sankyo (Inst)
Research Funding: Genentech (Inst), Bayer (Inst), Pfizer (Inst), Eisai (Inst), Eli Lilly (Inst), Boston Biomedical (Inst), Daiichi Sankyo (Inst), Array BioPharma (Inst)
Travel, Accommodations, Expenses: Genentech, Bayer, Bristol-Myers Squibb, Boston Biomedical, Amgen, Boehringer Ingelheim, Merck Sharp & Dohme

Eric Van Cutsem
Consulting or Advisory Role: Array, Bayer, Biocrates, Eli Lilly, Ipsi, Roche, Servier, Bristol-Myers Squibb, Celgene, Merck Sharp & Dohme, Merck KGaA, Novartis, AstaZeneca, Sirtex, Taiho, Pierre Fabre
Research Funding: Amgen (Inst), Bayer (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Novartis (Inst), Roche (Inst), Celgene (Inst), Ipsen (Inst), Merck (Inst), Merck KGaA (Inst), Servier (Inst), Bristol-Myers Squibb (Inst)

Rona Vaeger
Research Funding: Array Biopharma, GlaxoSmithKline, Novartis
Travel, Accommodations, Expenses: Array Biopharma

Harpreet Wasan
Honoraria: Merck KGaA, Celgene, Sirtex Medical, Servier, Array Biopharma, Shire, Genentech, ERYTECH Pharma, Amgen, Zymeworks, Pierre Fabre
Consulting or Advisory Role: Roche Pharma AG, Sirtex Medical, ERYTECH Pharma, Shire, Incyte
Speakers’ Bureau: Sirtex Medical, Celgene, Merck KGaA, Servier
Research Funding: Sirtex Medical (Inst), Merck KGaA (Inst), Pfizer (Inst), Merck Sharp & Dohme (Inst)

Takayuki Yoshino
Research Funding: Chugai Pharma (Inst), Sanofi (Inst), Sumitomo Dainippon (Inst), GlaxoSmithKline (Inst)

Jayesh Desai
Consulting or Advisory Role: Bionomics, Eli Lilly, Eisai, BeiGene, Ignyta (Inst)
Research Funding: Roche (Inst), GlaxoSmithKline (Inst), Novartis (Inst), Bionomics (Inst), MedImmune (Inst), BeiGene (Inst), Eli Lilly (Inst), Bristol-Myers Squibb (Inst)

Fortunato Cardiello
Consulting or Advisory Role: Genentech, Merck KGaA (Inst), Bayer, Amgen, Pfizer
Research Funding: Merck KGaA (Inst), Genentech (Inst), Servier (Inst), Symphogen (Inst), Amgen (Inst), Bayer (Inst), Merck Sharp & Dohme (Inst), Bristol-Myers Squibb (Inst), Ipsen (Inst)

Neeltje Steeghs
Consulting or Advisory Role: AIRM Therapeutics (Inst), Boehringer Ingelheim (Inst), Eisai (Inst), Eli Lilly (Inst)
Research Funding: AB Science (Inst), Abbvie (Inst), Actuate Therapeutics (Inst), Amgen (Inst), Array (Inst), AstraZeneca/MedImmune (Inst), Bayer (Inst), Blueprint Medicines (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cantargia (Inst), Cytovation (Inst), Deciphera (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), Incyte (Inst), InterNA (Inst), Lilly (Inst), Merck Sharp & Dohme (Inst), Menus (Inst), Novartis (Inst), Pfizer (Inst), Pierre Fabre (Inst), Roche (Inst), Sanofi (Inst), Taiho (Inst), Takeda (Inst)

Hendrik-Tobias Arkenau
Employment: Sarah Cannon Research Institute UK and HCA Healthcare UK
Advisory Boards: Roche, Servier, BioNTech, Beigene, Guardant, Bayer, iOnctura, Bicycle

Ashwin Gollerkeri
Employment: Pfizer

Janna Christy-Bittel
Employment: Pfizer (at time of research)

Scott Kopetz
Stock and Other Ownership Interests: MolecularMatch, Navire
Consulting or Advisory Role: Roche, Genentech, EMD Serono, Merck, Karyopharm Therapeutics, Amal Therapeutics, Navire Pharma, Symphogen, Holy Stone, Biocartis, Amal Therapeutics, Amgen, Novartis, Eli Lilly, Boehringer Ingelheim
Research Funding: Amgen (Inst), Sanofi (Inst), Biocartis (Inst), Guardant Health (Inst), Array BioPharma (Inst), Genentech (Inst), EMD Serono (Inst), MedImmune (Inst), Novartis (Inst)

No other potential conflicts of interest were reported.